Trial Profile
An Adaptive Design Study for the Assessment of the Pharmacokinetics of Albiglutide in Subjects With Normal Renal Function and Subjects With Moderate-to-Severe Renal Impairment and Hemodialysis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Albiglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors GSK
- 27 May 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 27 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.